Broad Institute of MIT and Harvard
Cambridge, Massachusetts, United States
Gad Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Getz is an institute member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. Getz is a professor of pathology at Harvard Medical School, and he is a faculty member and director of bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology. He is also the inaugural incumbent of the Paul C. Zamecnik Chair in Oncology at the MGH Cancer Center.
The Getz Laboratory specializes in cancer genome analysis, which includes two major steps. The first is characterization — cataloging of all genomic events and the mechanisms that created them during the clonal evolution of cancer (starting from normal cells and progressing to premalignancy, primary cancer, and the emergence of resistance), and comparing events at the DNA, RNA, and protein levels between tumor and normal samples from an individual patient. The second is interpretation — analysis of the characterization data across a cohort of patients with the aim of identifying the alterations in genes and pathways that drive cancer progression or increase its risk, as well as identifying molecular subtypes of the disease, their markers, and relationship to clinical variables.
In addition to his roles at the MGH and the Broad Institute, Getz is the PI of the Processing Genome Data Analysis Center, as part of the NCI Genome Data Analysis Network; a co-leader of the International Cancer Genome Consortium's Pan-Cancer Analysis of Whole Genomes project; and a co-PI of the Broad’s Proteogenomics Data Analysis Center. He has published numerous papers in prominent journals describing new methodologies to study cancer genomes that have identified new genes and pathways involved in different tumor types, mutational signatures, and tumor evolution.